COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)

Abstract

Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

We claim: 
     
         1 . A method for generating an immune response directed against a human Pegivirus 2 (HPgV-2) infection in a subject comprising: administering to a subject a composition comprising attenuated or inactivated HPgV-2 particles, and/or an antigenic portion of said HPgV-2, thereby generating an immune response in the subject directed against said HPgV-2. 
     
     
         2 . The method of  claim 1 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the S protein, the E1 protein, and the E2 protein. 
     
     
         3 . The method of  claim 1 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the X protein, the NS2 protein, and the NS3 protein. 
     
     
         4 . The method of  claim 1 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the NS4A protein, and the NS4B protein. 
     
     
         5 . The method of  claim 1 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the NS5A protein, and the NS5B protein. 
     
     
         6 . An immunogenic composition suitable for administration to a subject comprising: a composition comprising attenuated or inactivated HPgV-2 particles, and/or an antigenic portion of the HPgV-2. 
     
     
         7 . The composition of  claim 6 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the S protein, the E1 protein, and the E2 protein. 
     
     
         8 . The composition of  claim 6 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the X protein, the NS2 protein, and the NS3 protein. 
     
     
         9 . The composition of  claim 6 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the NS4A protein, and the NS4B protein. 
     
     
         10 . The composition of  claim 6 , wherein said antigenic portion of said HPgV-2 comprises a peptide, wherein said peptide comprises at least a portion of said HPgV-2 selected from the group consisting of: the NS5A protein, and the NS5B protein.